Article Text
Statistics from Altmetric.com
A 74-year-old woman gave a 6-month history of headache and intermittent face and arm movements. On initial examination, there were subtle right arm and leg choreiform movements. Her blood tests showed a low platelet count of 129×109/L (150–400), international normalised ratio of 1.2 (<1.4), erythrocyte sedimentation rate of 23 mm/first hour (<30), positive lupus anticoagulant, weakly positive anticardiolipin IgG at 25 IgG phospholipid units, positive IgM at 20 IgM phospholipid units and negative β2 glycoprotein-1. Eight weeks later, her symptoms progressed to manifest as continuous profound oromandibular choreiform movements (see online supplementary video 1 and figure 1), resulting in speech arrest and interfering with eating. Repeat blood tests showed persistent weakly positive anticardiolipin antibodies with positive lupus anticoagulant and a low platelet count. We gave her a trial of warfarin for probable antiphospholipid syndrome.1 Further investigations ruled out potential secondary antiphospholipid syndrome. Two weeks later, her choreiform movements resolved (see online supplementary video 2 and figure 2), as did her headaches. She has since been symptom-free for 18 months.
Supplemental material
Supplemental material
Although she had no history of pregnancy failure or recurrent thromboembolic events—required to meet the diagnostic criteria of definite antiphospholipid syndrome—the positive laboratory findings and clinical manifestation of chorea suggested probable antiphospholipid syndrome.2 This syndrome may involve any organ. Chorea comprises 1.3% of its neurological manifestations, although its cause is still poorly understood.
Chorea has only a few treatable causes. Antiphospholipid syndrome is one of them, and recognising the clinical and laboratory manifestations and instituting a trial of treatment can produce a good clinical outcome.
Footnotes
Contributors LZ wrote the case report. ACP contributed the discussion and edited the paper.
Competing interests None declared.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by Fady Joseph, South Wales, UK.
Linked Articles
Other content recommended for you
- Diagnosis and management of the antiphospholipid syndrome
- Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management
- Fitting and flailing: recognition of paediatric antiphospholipid syndrome
- High antiphospholipid antibody levels are associated with statin use and may reflect chronic endothelial damage in non-autoimmune thrombosis: cross-sectional study
- Thrombocytopenia in the antiphospholipid syndrome
- Antiphospholipid syndrome presenting as cerebral venous sinus thrombosis: a case series and a review
- Antiphospholipid antibodies and infections
- Obstetric antiphospholipid syndrome
- The antiphospholipid syndrome and its ‘non-criteria’ manifestations
- Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?